Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSAReal-world evidence of PYLARIFY’s effectiveness in ...

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

The imaging artificial intelligence developer Quibim has raised $50 million in venture capital funding, to support its work ...

The quest to advance detection and treatment of Alzheimer's disease and to personalize cancer care has received a major boost, with $7.2 million in funding to Lawson Research Institute (Lawson) of St.

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the ...

Artificial intelligence start-up Quibim has raised $50 million in first-round financing to support the rollout of its ...

US FDA grants fast track designation to Clarity Pharma’s Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer: Sydney, Australia Monday, January 27, 2025, 14:00 Hrs [I ...

Kala Krishnan, Director Of Allied Health Services (Radiotherapy/ Nuclear Medicine/ Imaging) of Beacon Hospital, leads a media tour to explain the advanced diagnostic technologies and treatments ...

GE HealthCare is researching imaging tech for improved diagnosis and treatment of patients with cancer and neurodegenerative ...

Learn more about whether Integra LifeSciences Holdings Corporation or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial ...

Several ASX companies understand the importance of early detection and treatment of cancer and are working to improve ...